Yi Chen

Yi Chen

Auto-generated profile, based on publicly available information

Yi Chen

Institute and Department of Endocrinology and Metabolism, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2020 in Diabetes Research and Clinical Practice
Verified
Journal Article
Closed access
HWHeng Wan
Heng Wan
YWYuying Wang
Yuying Wang
YCYi Chen
Yi Chen
SFSijie Fang
Sijie Fang
WZWen Zhang
Wen Zhang
YLYing-Li Lu
Ying-Li Lu

1 January 2019 in Therapeutic Advances in Musculoskeletal Disease
Verified
Journal Article
Open access
PDF file
WWWanlong Wu
Wanlong Wu
JMJun Ma
Jun Ma
YZYuhong Zhou
Yuhong Zhou
CTChao Tang
Chao Tang
FZFeng Zhao
Feng Zhao
YCYi Chen
Yi Chen
Infection remains a major cause of morbidity and mortality in patients with systemic lupus erythematosus (SLE). This study aimed to establish a clinical prediction model for the 3-month all-cause mortality of invasive infection events in patients with SLE in the emergency department. SLE patients complicated with invasive infection admitted into the emergency department were included in this study. Patient’s demographic, clinical, and laboratory characteristics on admission were retrospectively collected as baseline data and compared between the deceased and the survivors. Independent predictors were identified by multivariable logistic regression analysis. A prediction model for all-cause mortality was established and evaluated by receiver operating characteristic (ROC) curve analysis. A total of 130 eligible patients were collected with a cumulative 38.5% 3-month mortality. Lymphocyte count 7.6mmol/l, maximum prednisone dose in the past ⩾60 mg/d, quick Sequential Organ Failure Assessment (qSOFA) score, and age at baseline were independent predictors for all-cause mortality (LUPHAS). In contrast, a history of hydroxychloroquine use was protective. In a combined, odds ratio-weighted LUPHAS scoring system (score 3–22), patients were categorized to three groups: low-risk (score 3–9), medium-risk (score 10–15), and high-risk (score 16–22), with mortalities of 4.9% (2/41), 45.9% (28/61), and 78.3% (18/23) respectively. ROC curve analysis indicated that a LUPHAS score could effectively predict all-cause mortality [area under the curve (AUC) = 0.86, CI 95% 0.79–0.92]. In addition, LUPHAS score performed better than the qSOFA score alone (AUC = 0.69, CI 95% 0.59–0.78), or CURB-65 score (AUC = 0.69, CI 95% 0.59–0.80) in the subgroup of lung infections (n = 108). Based on a large emergency cohort of lupus patients complicated with invasive infection, the LUPHAS score was established to predict the short-term all-cause mortality, which could be a promising applicable tool for risk stratification in clinical practice.